<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01852461</url>
  </required_header>
  <id_info>
    <org_study_id>685.114A</org_study_id>
    <secondary_id>Surfactant trial</secondary_id>
    <nct_id>NCT01852461</nct_id>
  </id_info>
  <brief_title>Perfusion Index Variability in Respiratory Distress Syndrome</brief_title>
  <official_title>Perfusion Index Variability in Preterm Infants Treated With Two Different Natural Surfactants for Respiratory Distress Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Sami Ulus Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Sami Ulus Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Perfusion index may vary according to type of surfactant during the treatment of respiratory
      distress syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peripheral tissues of preterm infants are very sensitive for hypoperfusion, but there are
      rare data in the literature for peripheral perfusion after surfactant treatment. In this
      study the investigators aimed to compare the perfusion index (PI) variability in premature
      infants with respiratory distress (RDS) following instillation of one of two different
      natural surfactant preparations.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>perfusion index</measure>
    <time_frame>1 week</time_frame>
    <description>PI and oxygen saturation (SpO2) were measured by &quot;Masimo Rainbow SET Radical-7 pulse oximeter&quot; before and after surfactant. The effects of the two treatment regimens on PI, oxygenation and clinical outcome were compared.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>4 weeks</time_frame>
    <description>The effects of the two treatment regimens on duration of mechanical ventilation were compared</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Mortality</measure>
    <time_frame>4 weeks</time_frame>
    <description>The effects of the two treatment regimens on mortality were compared</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Poor Peripheral Perfusion</condition>
  <arm_group>
    <arm_group_label>Beractant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Beractant;bovine lung extract; both initial and subsequent dosing is 100 mg/kg (4 mL/kg), which may be given every 6 hours up to four total doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Poractant alfa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Poractant alfa; porcine lung extract; initial dosing is 200 mg/kg (2.5 mL/kg) and repeated dosing is given at 100 mg/kg (1.25 mL/kg) every 12 hours, up to maximum of two additional doses when indicated</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beractant</intervention_name>
    <description>Beractant;both initial and subsequent dosing is 100 mg/kg (4 mL/kg), which may be given every 6 hours up to four total doses</description>
    <arm_group_label>Beractant</arm_group_label>
    <other_name>Beractant (Survanta)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Poractant alfa</intervention_name>
    <description>porcine lung extract, initial dosing is 200 mg/kg (2.5 mL/kg) and repeated dosing is given at 100 mg/kg (1.25 mL/kg) every 12 hours, up to maximum of two additional doses when indicated</description>
    <arm_group_label>Poractant alfa</arm_group_label>
    <other_name>Poractant alfa (curosurf)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  premature infants &lt; 32 weeks of gestational age

        Exclusion Criteria:

          -  congenital malformation

          -  Apgar scores &lt;3 at 5 min
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dilek Dilli, Assoc Prof</last_name>
    <role>Study Director</role>
    <affiliation>Sami Ulus CH</affiliation>
  </overall_official>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2013</study_first_submitted>
  <study_first_submitted_qc>May 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2013</study_first_posted>
  <last_update_submitted>May 10, 2013</last_update_submitted>
  <last_update_submitted_qc>May 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dr. Sami Ulus Children's Hospital</investigator_affiliation>
    <investigator_full_name>Dilek Dilli</investigator_full_name>
    <investigator_title>Assos Prof</investigator_title>
  </responsible_party>
  <keyword>natural surfactants; perfusion index</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poractant alfa</mesh_term>
    <mesh_term>Beractant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

